[go: up one dir, main page]

TN2009000544A1 - Derives de benzimidazole - Google Patents

Derives de benzimidazole

Info

Publication number
TN2009000544A1
TN2009000544A1 TNP2009000544A TN2009000544A TN2009000544A1 TN 2009000544 A1 TN2009000544 A1 TN 2009000544A1 TN P2009000544 A TNP2009000544 A TN P2009000544A TN 2009000544 A TN2009000544 A TN 2009000544A TN 2009000544 A1 TN2009000544 A1 TN 2009000544A1
Authority
TN
Tunisia
Prior art keywords
benzimidazole derivatives
mammals
compounds
treatment
cell growth
Prior art date
Application number
TNP2009000544A
Other languages
English (en)
Inventor
Christopher Scott Jones
GRECA Susan LA
Qifang Li
Michael John Munchhof
Lawrence Alan Reiter
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TN2009000544A1 publication Critical patent/TN2009000544A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé de formule (I) ou un de ses sels pharmaceutiquement acceptables, formule dans laquelle R1, R2, R3A, R3B, R4, R5, X, m et n sont tels que définis ici. Ces dérivés de benzamidazole nouveaux sont utiles dans le traitement de la croissance cellulaire anormale, telle qu'un cancer, chez des mammifères. Cette invention concerne également un procédé d'utilisation de ces composés dans le traitement de la croissance cellulaire anormale chez des mammifères, notamment des êtres humains, et des compositions pharmaceutiques contenant ces composés.
TNP2009000544A 2007-06-29 2009-12-25 Derives de benzimidazole TN2009000544A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02
PCT/IB2008/001575 WO2009004427A2 (fr) 2007-06-29 2008-06-16 Dérivés de benzamidazole

Publications (1)

Publication Number Publication Date
TN2009000544A1 true TN2009000544A1 (fr) 2011-03-31

Family

ID=40161351

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000544A TN2009000544A1 (fr) 2007-06-29 2009-12-25 Derives de benzimidazole

Country Status (45)

Country Link
US (2) US8148401B2 (fr)
EP (1) EP2170860B9 (fr)
JP (2) JP4567099B2 (fr)
KR (1) KR101143246B1 (fr)
CN (1) CN101687841B (fr)
AP (1) AP2377A (fr)
AR (1) AR067346A1 (fr)
AU (1) AU2008272641B2 (fr)
BR (1) BRPI0813412B8 (fr)
CA (1) CA2690953C (fr)
CL (1) CL2008001922A1 (fr)
CO (1) CO6160232A2 (fr)
CR (1) CR11150A (fr)
CU (1) CU23847B1 (fr)
CY (2) CY1118650T1 (fr)
DK (1) DK2170860T5 (fr)
DO (1) DOP2009000278A (fr)
EA (1) EA016888B1 (fr)
EC (1) ECSP099803A (fr)
ES (1) ES2609258T3 (fr)
FR (1) FR20C1038I2 (fr)
GE (1) GEP20125702B (fr)
GT (1) GT200900328A (fr)
HN (1) HN2008000974A (fr)
HR (1) HRP20161562T2 (fr)
HU (2) HUE030052T4 (fr)
IL (1) IL202420A (fr)
LT (2) LT2170860T (fr)
MA (1) MA31466B1 (fr)
ME (1) ME00962B (fr)
MY (1) MY148636A (fr)
NI (1) NI200900219A (fr)
NL (1) NL301057I2 (fr)
NO (1) NO2020027I1 (fr)
NZ (1) NZ581889A (fr)
PA (1) PA8785401A1 (fr)
PE (2) PE20090772A1 (fr)
PL (1) PL2170860T3 (fr)
PT (1) PT2170860T (fr)
RS (1) RS55395B9 (fr)
SI (1) SI2170860T1 (fr)
TN (1) TN2009000544A1 (fr)
TW (1) TWI371451B (fr)
UY (1) UY31164A1 (fr)
WO (1) WO2009004427A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009004427A2 (fr) * 2007-06-29 2009-01-08 Pfizer Inc. Dérivés de benzamidazole
EP2330894B8 (fr) 2008-09-03 2017-04-19 BioMarin Pharmaceutical Inc. Compositions comprenant des dérivés d acide 6-aminohexanoïque utilisées comme inhibiteurs de hdac
MX2011013294A (es) * 2009-06-11 2012-01-12 Siena Biotech Spa Antagonistas de la trayectoria de hedgehog y aplicaciones terapeuticas de los mismos.
NZ598749A (en) 2009-08-26 2013-01-25 Takeda Pharmaceutical Fused heterocyclic ring derivative and use thereof
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
EP2630134B9 (fr) 2010-10-20 2018-04-18 Pfizer Inc Dérivés de 2-pyridine comme modulateurs du récepteur smoothened
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Ｎｔｔドコモ ホーム基地局及びハンドオーバ方法
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CA3061239A1 (fr) 2011-02-28 2012-09-07 Biomarin Pharmaceutical Inc. Inhibiteurs de l'histone deacetylase
EP2684167B1 (fr) 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions et méthodes utiles dans le traitement de maladies
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
ES2612934T3 (es) 2011-09-26 2017-05-19 Merck Patent Gmbh Compuestos de piperidin bencilo como antagonista del receptor del ácido lisofosfatídico (LPA)
US20150150869A1 (en) 2012-06-20 2015-06-04 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2922544B1 (fr) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Méthodes et compositions utiles dans le traitement de maladies faisant appel à des protéines de la famille bcl-2 avec des dérivés de quinoléine
CN105121415B (zh) 2013-03-15 2018-10-12 生物马林药物股份有限公司 Hdac抑制剂
EP2996689A1 (fr) 2013-04-17 2016-03-23 Albert-Ludwigs-Universität Freiburg Composés destinés à être utilisés comme inhibiteurs de bromodomaine
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
DK3666768T3 (da) 2015-04-24 2022-06-27 Pfizer F r e m g a n g s m å d e t i l f r e m s t i l l i n g a f e n k r y s t a l l i n s k f o r m a f 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleat; krystallinsk form af 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-YL)-1-methylpiperidin-4-YL)-3-(4-cyanophenyl)ure
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2020164722A (ja) * 2019-03-29 2020-10-08 デクセリアルズ株式会社 接着剤組成物
US20230107634A1 (en) 2020-01-28 2023-04-06 Teva Pharmaceuticals International Gmbh Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
WO2021191278A1 (fr) 2020-03-26 2021-09-30 Lek Pharmaceuticals D.D. Forme dimaléate de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-méthylpipéridine -4-yl)-3-(4-cyanophényl)urée
WO2021261601A1 (fr) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 Méthode de sélection d'un patient cancéreux pour lequel une polythérapie d'un rétinoïde et d'un agent de traitement du cancer sera efficace, et médicament combiné d'un rétinoïde et d'un agent de traitement du cancer
WO2023002362A1 (fr) 2021-07-22 2023-01-26 Pfizer Inc. Traitement d'une malignité hématologique

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4658473B2 (ja) 2001-07-27 2011-03-23 キュリス，インコーポレイテッド ヘッジホッグシグナル伝達経路メディエーター、それに関連した組成物及び利用
WO2003048154A1 (fr) * 2001-12-04 2003-06-12 Actelion Pharmaceuticals Ltd Nouveaux derives de quinoleines
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2004035549A1 (fr) 2002-10-17 2004-04-29 Amgen Inc. Derives de benzimidazoles et utilisation de ceux-ci en tant que ligands du recepteur vanilloide
WO2005042495A1 (fr) 2003-10-21 2005-05-12 Imclone Systems Incorporated Composes de (benzimidazol-2-yl)-phenyl-phenyl-uree et procedes d'inhibition de l'activite de l'heparanase
US7309716B2 (en) 2003-10-28 2007-12-18 Vertex Pharmaceuticals Incorporated Benzimidazoles useful as modulators of ion channels
EP1807074B1 (fr) * 2004-11-03 2013-10-23 Curis, Inc. Mediateurs de voies de signalisation hedgehog, compositions et utilisations liees a ceux-ci
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (fr) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
WO2008064830A1 (fr) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Dérivés bicycliques et hétérobicycliques, leurs procédés de fabrication et leurs utilisations pharmaceutiques
EP2121626A1 (fr) 2006-12-15 2009-11-25 Pfizer Products Inc. Dérivés du benzamidazole
WO2009004427A2 (fr) 2007-06-29 2009-01-08 Pfizer Inc. Dérivés de benzamidazole
US20120094974A1 (en) 2008-06-17 2012-04-19 Wei Chen Smoothened receptor modulators
EP2328871B1 (fr) 2008-08-25 2020-04-01 Novartis AG Modulateurs de la voie hedgehog

Also Published As

Publication number Publication date
AU2008272641A1 (en) 2009-01-08
CY2020028I2 (el) 2020-11-25
PA8785401A1 (es) 2009-01-23
MA31466B1 (fr) 2010-06-01
ECSP099803A (es) 2010-01-29
EP2170860A2 (fr) 2010-04-07
EA016888B1 (ru) 2012-08-30
US20090005416A1 (en) 2009-01-01
LTPA2020528I1 (lt) 2020-09-25
CA2690953A1 (fr) 2009-01-08
HUE030052T2 (hu) 2017-04-28
ME00962B (fr) 2012-06-20
GEP20125702B (en) 2012-12-10
IL202420A (en) 2014-05-28
LT2170860T (lt) 2017-01-10
HN2008000974A (es) 2011-01-24
HK1139658A1 (en) 2010-09-24
KR101143246B1 (ko) 2012-05-18
HUS2000031I1 (hu) 2020-09-28
CL2008001922A1 (es) 2009-01-02
CY1118650T1 (el) 2017-07-12
SI2170860T1 (sl) 2017-01-31
NL301057I2 (nl) 2020-09-10
CN101687841B (zh) 2013-07-10
RS55395B1 (sr) 2017-04-28
TW200911792A (en) 2009-03-16
EP2170860B1 (fr) 2016-11-02
CU20090225A7 (es) 2012-02-15
CY2020028I1 (el) 2020-11-25
FR20C1038I2 (fr) 2021-08-13
CN101687841A (zh) 2010-03-31
IL202420A0 (en) 2010-06-30
BRPI0813412B8 (pt) 2021-05-25
EP2170860B9 (fr) 2017-02-22
WO2009004427A3 (fr) 2009-06-04
US20120157495A1 (en) 2012-06-21
AU2008272641B2 (en) 2013-08-29
HRP20161562T2 (hr) 2017-04-21
PE20121010A1 (es) 2012-08-06
DK2170860T3 (en) 2017-01-09
JP4567099B2 (ja) 2010-10-20
UY31164A1 (es) 2009-01-30
ES2609258T3 (es) 2017-04-19
DK2170860T5 (en) 2017-03-20
AP2009005089A0 (en) 2009-12-31
CR11150A (es) 2010-02-08
JP2010280693A (ja) 2010-12-16
CU23847B1 (es) 2012-10-15
HRP20161562T1 (hr) 2016-12-30
TWI371451B (en) 2012-09-01
PL2170860T3 (pl) 2017-05-31
CA2690953C (fr) 2012-10-02
HUE030052T4 (en) 2017-06-28
LTC2170860I2 (lt) 2022-03-10
DOP2009000278A (es) 2009-12-31
BRPI0813412B1 (pt) 2020-01-21
PT2170860T (pt) 2017-01-04
KR20100028120A (ko) 2010-03-11
RS55395B9 (sr) 2020-01-31
AP2377A (en) 2012-03-07
GT200900328A (es) 2011-08-29
FR20C1038I1 (fr) 2020-10-02
WO2009004427A2 (fr) 2009-01-08
EA200971104A1 (ru) 2010-06-30
NL301057I1 (nl) 2020-07-22
NZ581889A (en) 2011-05-27
US8148401B2 (en) 2012-04-03
NI200900219A (es) 2010-03-11
PE20090772A1 (es) 2009-06-24
US8431597B2 (en) 2013-04-30
CO6160232A2 (es) 2010-05-20
MY148636A (en) 2013-05-15
NO2020027I1 (no) 2020-08-11
JP2010531869A (ja) 2010-09-30
BRPI0813412A2 (pt) 2014-12-30
AR067346A1 (es) 2009-10-07

Similar Documents

Publication Publication Date Title
TN2009000544A1 (fr) Derives de benzimidazole
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA28747B1 (fr) Dérivés de pyridine
MA29926B1 (fr) Derives de pyrazine
TN2009000450A1 (fr) Derives de pyridine
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA31373B1 (fr) Composes amino-heterocycliques
TN2009000138A1 (fr) Biaryl-ether-urees
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA29909B1 (fr) Derives de pyridazine
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
DK1678166T3 (da) Proteinkinaseinhibitorer
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
EP2102225A4 (fr) Dérivés d'alpha-galactosylceramide, sels pharmaceutiquement acceptables de ceux-ci, procédé de préparation et composition pharmaceutique d'adjuvant immunologique contenant ces composés comme principe actif
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
MA24729A1 (fr) Macrolides nouveaux.
BR0308146A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto